(Reuters) – A roundup of some of the recent clinical research on the novel coronavirus and attempts to classify therapies and vaccines for the virus-induced disease COVID-19 is presented below.
According to data from a continuing mid-stage review, an experimental COVID-19 vaccine from Johnson & Johnson developed protective antibodies against the novel coronavirus in 90 percent of 805 volunteers by 29 days, and that increased to 100 percent by day 57. Side effects such as fever, muscle aches and pain at the injection site were easily overcome, researchers reported in the New England Journal of Medicine on Wednesday.
The likelihood of good results “hopefully is very high,” the New Brunswick, New Jersey-based company’s chief scientific officer Paul Stoffels said this week. (bit.ly/2LpBhHm)
For at least five months, COVID-19 survivors are highly likely to have some immune immunity against the virus, and reinfections in recovered patients are rare, with only 44 cases found among 6,614 previously infected individuals, according to researchers leading a large-scale ongoing study of British health workers. But if people get COVID-19 for the second time, they sometimes don’t have any symptoms, and so on.
“We now know that most of those who have had the virus, and developed antibodies, are protected from reinfection, but this is not total and we do not yet know how long protection lasts,” said study leader Susan Hopkins, senior medical adviser at PHE in London. “If you believe you already had the disease and are protected, you can be reassured it is highly unlikely you will develop severe infections. But there is still a risk you could acquire an infection and transmit (it) to others.” (bit.ly/3ihkuBZ; reut.rs/3ieWorA)